About Bioline  All Journals  Testimonials  Membership  News  Donations

Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482
EISSN: 1998-4138
Vol. 5, No. 4, 2009, pp. 254-262
Bioline Code: cr09062
Full paper language: English
Document type: Research Article
Document available free of charge

Journal of Cancer Research and Therapeutics, Vol. 5, No. 4, 2009, pp. 254-262

 en Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma
Pervez, Shahid; Nasir, Muhammd I.; Moatter, Tariq; Ahsan, Adeeb; Haq, Amna & Siddiqui, Tariq


Background: This study was conducted to analyze the frequency, expression patterns, and the impact of individual proteins BCL2, BCL6, and p53 on overall survival (OS) in adult, diffuse large B-cell lymphoma (DLBCL) patients. BCL2 gene was further investigated for potential alterations at the DNA level and correlated with OS.
Materials and Methods
: A total of 117 adult well-characterized DLBCL cases were included. The panel of antibodies comprised CD45, CD20, CD79a, CD3, BCL2, BCL6, and p53. PCR was also employed to correlate the events at the DNA level in BCL2.
: The mean and median ages were 47.74 and 49 with a M:F ratio of 2.07:1. The incidence of BCL2, BCL6, and p53 expression was observed in 64.10%, 37.60%, and 52.13% of cases, respectively. Amplifiable quality DNA was available from 90 cases. BCL2/IGH translocation was found in 35/90 patients (38.88%) with 24 cases showing BCL2 (MBR)/IGH and 11 cases BCL2 (mcr)/IGH translocation. No association between BCL2 overexpression and BCL2 /IGH translocation was seen. Clinical data were available for 52 patients treated by CHOP therapy. It was found that patients with p53 overexpression had decreased overall survival (P = 0.0004) whereas BCL2, BCL6 expression, and BCL2/IGH translocation had no impact on overall survival.
: Our data suggest that simple p53 protein expression by IHC at the time of diagnosis may help to identify high-risk patients, who may benefit with more aggressive and newer treatments in addition to standard CHOP.

BCL2, BCL6, p53, BCL2/IGH translocation, DLBCL, overall survival

© Copyright 2009 Journal of Cancer Research and Therapeutics.
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 09-Nov-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil